Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01262391
Other study ID # 905-CL-075
Secondary ID 2009-017197-21
Status Completed
Phase Phase 1
First received
Last updated
Start date October 20, 2010
Est. completion date August 14, 2011

Study information

Verified date October 2018
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This single-dose study will investigate how well solifenacin suspension is taken up, how long it stays in the body and how well it will be tolerated in children and adolescents aged 5-17 years with symptoms of overactive bladder.


Description:

This is a multicenter, open-label, sequential, single ascending dose study. The study will consist of three treatment groups in children and three treatment groups in adolescents, targeting equivalent exposure to the 2.5, 5 and 10 mg doses o.d. in adults at steady state. The study will be conducted in pediatric OAB patients to establish the single-dose PK and the acute safety profile of solifenacin aqueous suspension. Each of the six groups will consist of at least six patients.

The study will start with the lowest dose group in adolescent patients (12 to 17 years). When this group has completed the study, their safety and concentration data will be reviewed by a Safety Review Committee. If no safety concerns are evident according to pre-specified criteria, enrollment of children (5 to 11 years) in the lowest dose group and adolescents in the intermediate dose group will be started simultaneously. When these groups have completed the study, their safety data and drug concentration data will also be reviewed. If no safety concerns occurred, enrollment of children in the intermediate dose group and of adolescents in the highest dose group will be started simultaneously. Finally, after these groups completed the study and no safety concerns occurred during associated data review, enrollment of children in the highest dose group will start. Interim review of plasma exposure at lower doses will be used to adjust the next higher doses administered, if necessary.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date August 14, 2011
Est. primary completion date August 14, 2011
Accepts healthy volunteers No
Gender All
Age group 5 Years to 17 Years
Eligibility Inclusion Criteria:

- Symptoms of urgency, diagnosed as OAB according to International Children's Continence Society (ICCS) criteria

- Daytime urgency incontinence at least once/day

Exclusion Criteria:

- Daytime voiding frequency less than 5

- Uroflow indicative of pathology other than OAB

- Maximum voided volume > age expected capacity ([age +1] x 30) in ml

- Post voiding residual (PVR) > 10% of the functional bladder capacity

- Monosymptomatic enuresis

- Congenital anomalies of the genito-urinary tract or nervous system

- Current constipation (when treated the patient can enter the study)

- Current urinary tract infection (patient will be eligible for enrolment 14 days after a negative dipstick test, provided a second dipstick test, performed after these 14 days, is also negative)

- Serum creatinine more than or equal to 2 times the upper limit of normal (ULN)

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than or equal to 2 times ULN, or bilirubin more than or equal to 1.5 times ULN

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Solifenacin succinate suspension 2.5 mg
Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 2.5 mg of solifenacin once daily in adults.
Solifenacin succinate suspension 5 mg
Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 5 mg dose of solifenacin once daily in adults.
Solifenacin succinate suspension 10 mg
Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses 10 mg dose of solifenacin once daily in adults.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma Inc

Countries where clinical trial is conducted

Belgium,  Denmark,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Concentration (Cmax) Day 1 predose up to Day 7 postdose
Primary Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) Day 1 predose up to Day 7 postdose
Primary Apparent Terminal Elimination Half-life (t1/2) Day 1 predose up to Day 7 postdose
Primary Time to Attain Cmax (tmax) Day 1 predose up to Day 7 postdose
Primary Area Under the Concentration-time Curve from the Time of Dosing Until the Last Measurable Concentration (AUClast) Day 1 predose up to Day 7 postdose
Primary Apparent Total Body Clearance (CL/F) Day 1 predose up to Day 7 postdose
Primary Apparent Volume of Distribution During the Terminal Phase (Vz/F) Day 1 predose up to Day 7 postdose
Secondary Number of Participants with Adverse Events (AEs) Safety is monitored by collecting AEs, which includes abnormal laboratory tests, vital signs or ECG data that are defined as an AE if the abnormality induces clinical signs or symptoms, requires active intervention, interruption or discontinuation of study medication or is clinically significant in the investigator's opinion. A treatment-emergent adverse event (TEAE) is defined as an AE that occurs or worsens after study drug administration. A serious AE (SAE) is any untoward medical occurrence that, at any dose: Results in death, is life-threatening, results in persistent or significant disability/incapacity, results in congenital anomaly, or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization or other medically important events. From the first dose of study drug up to 7 days postdose
Secondary Change from baseline in postvoid residual (PVR) volume PVR volume is assessed by ultrasonography or bladder scan. Baseline (screening) and 4 hours postdose
See also
  Status Clinical Trial Phase
Recruiting NCT06201013 - Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children N/A
Recruiting NCT05880862 - Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls Early Phase 1
Recruiting NCT04807920 - BOTOX® at the Time of Prolapse Surgery for OAB Phase 4
Terminated NCT02385500 - Fesoterodine on Urgency Episodes in Parkinson's Disease Population Phase 4
Not yet recruiting NCT02477241 - Brain Areas Involved in Bladder Filling and Contraction N/A
Completed NCT01698138 - Prevention of Bladder Dysfunction in Acute Spinal Cord Injury Phase 4
Completed NCT00613327 - An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants Phase 4
Completed NCT00527033 - A Study of YM178 in Patients With Symptomatic Overactive Bladder Phase 2
Completed NCT00368706 - A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients Phase 3
Recruiting NCT04305743 - Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A Phase 4
Active, not recruiting NCT03681678 - Laser Therapy for Treatment of Urogenital Symptoms in Women
Completed NCT01655069 - A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 Phase 3
Completed NCT01558856 - Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder N/A
Completed NCT01521767 - Pharmacokinetics and Relative Bioavailability Study Phase 1
Completed NCT01157377 - Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence Phase 2
Completed NCT01381120 - Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms Phase 4
Completed NCT01194999 - Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence Phase 4
Completed NCT04528784 - Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis N/A
Completed NCT02849418 - Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity Phase 3
Recruiting NCT05968885 - Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity Phase 4